AI and the Pharmaceutical Industry — 2026-10-10 (Sat)

Overview

Today's focus is capital flowing into AI drug discovery companies. Isomorphic Labs is seeking to raise funds at a $40 Billion valuation, and Iambic is aiming to raise $150 million (planned/expected) in an IPO. Together with the $1.8 Billion committed by the Virtual Biology Initiative, private capital is moving toward both the foundational data for drug discovery AI and the specialist companies. On the large-pharma side, there are reports that Pfizer handed AI to its business-unit leaders, which accelerated adoption.

By Category

In drug discovery, valuation figures are coming out ahead of actual deals. Isomorphic Labs' $40 Billion is the level it hopes to reach in its raise, not a confirmed transaction price. Phyraxis AI's initial funding was reported in the context of $3B flowing into the physical AI space, so that figure is not the amount raised by any single company. The Virtual Biology Initiative is pooling $1.8 Billion to build open AI training data for drug discovery. This can be read as an effort to close gaps in model performance through shared data.

In enterprise-wide AI infrastructure and governance, Iambic's IPO stands out. Its valuation is given as $800M+, but the headline does not make clear whether this is an upper or lower bound, so it cannot be treated as a confirmed figure. The amount to be raised is $150 million, and another report puts it at up to USD 159m; both are plans or expectations. It has also been reported that Iambic is backed by Nvidia. Among pharma-related moves, Cognizant extended its partnership with Gilead Sciences to AI-enabled DevOps. Bayer sold Blackford Analysis to Sopris Capital, which plans to merge it with Azra AI. Pfizer's case stands out as an adoption approach that prioritizes rollout on the front lines over building out the underlying infrastructure.

Reading the Investment Map

Money is going, first, to specialist AI drug discovery companies. Isomorphic Labs' $40 Billion and Iambic's $800M+ are both valuations, not completed transactions. Iambic's $150 million is the amount it expects to raise in its IPO (planned/expected). Second, as the Virtual Biology Initiative's $1.8 Billion shows, funding is going to training data as a shared foundation. Third, Bayer's sale of Blackford Analysis shows a large company carving out peripheral AI assets. Tempus AI's Q2 $382.5M is the company's own financial result. It was reported alongside a deal for an oncology model for AstraZeneca, but the headline alone does not establish it as an investment amount.

What to Watch

Whether Isomorphic Labs' fundraising closes, and if so, whether the valuation reaches $40 Billion. 2. Whether Iambic's IPO proceeds to pricing, and whether the valuation and amount raised match the plan.